Why the study?
Does a genotype-guided approach improve drug effectiveness or reduce toxicity compared to a clinical approach in stroke management?
Does a genotype-guided approach improve drug effectiveness or reduce toxicity compared to a clinical approach in stroke management?
Current evidence does not support the routine use of pharmacogenetic testing to guide drug therapy in stroke management.
Does not support routine pharmacogenetic testing in stroke; leaves open need for definitive trials to establish benefit.
Stroke is the third cause of mortality and one of most frequent causes of long-term neurological disability, as well as a complex disease that results from the interaction of environmental and genetic factors. The focus on genetics has produced a large number of studies with the objective of revealing the genetic basis of cerebrovascular diseases. Furthermore, pharmacogenetic research has investigated the relation between genetic variability and drug effectiveness/toxicity. This review will examine the implications of pharmacogenetics of stroke; data on antihypertensives, statins, antiplatelets, anticoagulants, and recombinant tissue plasminogen activator will be illustrated. Several polymorphisms have been studied and some have been associated with positive drug-gene interaction on stroke, but the superiority of the genotype-guided approach over the clinical approach has not been proved yet; for this reason, it is not routinely recommended.
No takes yet. Share an insight, caveat, or question.
Amici et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: